IndiumV1, Main, Exploration, bibRecord, 000207

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

Identifieur interne : 000207 ( Main/Exploration ); précédent : 000206; suivant : 000208

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

Auteurs : RBID : ISTEX:259_1994_Article_BF00285586.pdf

English descriptors

KwdEn :
- Biodistribution, Indium, Ligands, Monoclonal antibodies, Yttrium.

Abstract

The biodistribution of indium-111/yttrium-88-labeled B3 monoclonal antibody, a murine IgG1k, was evaluated in non-tumor-bearing mice. B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4–2.4 mCi/mg and 88Y at 0.1–0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5–10 μCi/4–10 μg of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection. Mice injected with 111In/88Y (IB4M)-B3 showed a similar biodistribution of the two radiolabels in all tissues except the bones, where significantly higher accretion of 88Y than 111In was observed, with 2.8% ± 0.2% vs 1.3% ± 0.16% ID/g in the femur at 168 h, respectively (P<0.0001). In contrast, mice receiving the 111In/88Y-(DOTA)-B3 conjugate showed significantly higher accumulation of 111In than 88Y in most tissues, including the bones, with 2.0% ± 0.1% vs 1.2% ± 0.09% ID/g in the femur at 168 h, respectively (P<0.0001). Whereas the ratios of the areas underneath the curve (%ID × h/g) in the blood, liver, kidney and bone were 0.96, 1.12, 1.13, and 0.74 for 111In/88Y-(IB4M)-B3 and 0.84, 1.23, 1.56, and 1.31 for 111In/88Y (DOTA)-B3, respectively, ratios ≈ 1 were observed between 111In-(IB4M)-B3 and 88Y-(DOTA)-B3. In summary, while neither IB4M nor DOTA was equally stable for 111In and 88Y, the fate of 88Y- (DOTA)-B3 could be closely traced by that of 111 In-(IB4M)-B3.

DOI: 10.1007/BF00285586

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000865
to stream Main, to step Curation: 000865

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title>Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)</title>
<author><name>Luigi Camera</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Seigo Kinuya</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Kayhan Garmestani</name>
<affiliation wicri:level="1"><mods:affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Martin W. Brechbiel</name>
<affiliation wicri:level="1"><mods:affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Chuanchu Wu</name>
<affiliation wicri:level="1"><mods:affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Lee H. Pai</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Thomas J. McMurry</name>
<affiliation wicri:level="1"><mods:affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Otto A. Gansow</name>
<affiliation wicri:level="1"><mods:affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Ira Pastan</name>
<affiliation wicri:level="1"><mods:affiliation>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Chang H. Paik</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name>Jorge A. Carrasquillo</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="RBID">ISTEX:259_1994_Article_BF00285586.pdf</idno>
<date when="1994">1994</date>
<idno type="doi">10.1007/BF00285586</idno>
<idno type="wicri:Area/Main/Corpus">000865</idno>
<idno type="wicri:Area/Main/Curation">000865</idno>
<idno type="wicri:Area/Main/Exploration">000207</idno>
</publicationStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Biodistribution</term>
<term>Indium</term>
<term>Ligands</term>
<term>Monoclonal antibodies</term>
<term>Yttrium</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="eng">The biodistribution of indium-111/yttrium-88-labeled B3 monoclonal antibody, a murine IgG1k, was evaluated in non-tumor-bearing mice. B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4–2.4 mCi/mg and 88Y at 0.1–0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5–10 μCi/4–10 μg of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection. Mice injected with 111In/88Y (IB4M)-B3 showed a similar biodistribution of the two radiolabels in all tissues except the bones, where significantly higher accretion of 88Y than 111In was observed, with 2.8% ± 0.2% vs 1.3% ± 0.16% ID/g in the femur at 168 h, respectively (P<0.0001). In contrast, mice receiving the 111In/88Y-(DOTA)-B3 conjugate showed significantly higher accumulation of 111In than 88Y in most tissues, including the bones, with 2.0% ± 0.1% vs 1.2% ± 0.09% ID/g in the femur at 168 h, respectively (P<0.0001). Whereas the ratios of the areas underneath the curve (%ID × h/g) in the blood, liver, kidney and bone were 0.96, 1.12, 1.13, and 0.74 for 111In/88Y-(IB4M)-B3 and 0.84, 1.23, 1.56, and 1.31 for 111In/88Y (DOTA)-B3, respectively, ratios ≈ 1 were observed between 111In-(IB4M)-B3 and 88Y-(DOTA)-B3. In summary, while neither IB4M nor DOTA was equally stable for 111In and 88Y, the fate of 88Y- (DOTA)-B3 could be closely traced by that of 111 In-(IB4M)-B3.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="96b66e6add01e5fdf9cc3bdf70d3999cdaaf90ef"><titleInfo lang="eng"><title>Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)</title>
</titleInfo>
<name type="personal"><namePart type="given">Luigi</namePart>
<namePart type="family">Camera</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Seigo</namePart>
<namePart type="family">Kinuya</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Kayhan</namePart>
<namePart type="family">Garmestani</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Martin W.</namePart>
<namePart type="family">Brechbiel</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Chuanchu</namePart>
<namePart type="family">Wu</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Lee H.</namePart>
<namePart type="family">Pai</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Thomas J.</namePart>
<namePart type="family">McMurry</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Otto A.</namePart>
<namePart type="family">Gansow</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Chemistry Section, Radiation Oncology Branch, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Ira</namePart>
<namePart type="family">Pastan</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Chang H.</namePart>
<namePart type="family">Paik</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<name type="personal"><namePart type="given">Jorge A.</namePart>
<namePart type="family">Carrasquillo</namePart>
<role><roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, Warren G. Magnuson Clinical Center, National Institutes of Health, 9000 Rockville Pike, 20892, Bethesda, MD, USA</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1993-11-02</dateCreated>
<dateValid encoding="w3cdtf">2004-08-14</dateValid>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<language><languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription><internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">The biodistribution of indium-111/yttrium-88-labeled B3 monoclonal antibody, a murine IgG1k, was evaluated in non-tumor-bearing mice. B3 was conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1B4M) or 2-(p-SCN-Bz)-1,4,7,10 tetraazacyclododecane tetra-acetic acid (2B-DOTA) and labeled with 111In at 1.4–2.4 mCi/mg and 88Y at 0.1–0.3 mCi/mg. Non-tumor-bearing nude mice were co-injected i.v. with 5–10 μCi/4–10 μg of 111In/88Y-labeled B3 conjugates and sacrificed at 6 h and daily up to 168 h post-injection. Mice injected with 111In/88Y (IB4M)-B3 showed a similar biodistribution of the two radiolabels in all tissues except the bones, where significantly higher accretion of 88Y than 111In was observed, with 2.8% ± 0.2% vs 1.3% ± 0.16% ID/g in the femur at 168 h, respectively (P<0.0001). In contrast, mice receiving the 111In/88Y-(DOTA)-B3 conjugate showed significantly higher accumulation of 111In than 88Y in most tissues, including the bones, with 2.0% ± 0.1% vs 1.2% ± 0.09% ID/g in the femur at 168 h, respectively (P<0.0001). Whereas the ratios of the areas underneath the curve (%ID × h/g) in the blood, liver, kidney and bone were 0.96, 1.12, 1.13, and 0.74 for 111In/88Y-(IB4M)-B3 and 0.84, 1.23, 1.56, and 1.31 for 111In/88Y (DOTA)-B3, respectively, ratios ≈ 1 were observed between 111In-(IB4M)-B3 and 88Y-(DOTA)-B3. In summary, while neither IB4M nor DOTA was equally stable for 111In and 88Y, the fate of 88Y- (DOTA)-B3 could be closely traced by that of 111 In-(IB4M)-B3.</abstract>
<subject lang="eng"><genre>Key words</genre>
<topic>Indium</topic>
<topic>Yttrium</topic>
<topic>Biodistribution</topic>
<topic>Monoclonal antibodies</topic>
<topic>Ligands</topic>
</subject>
<relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo><title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1994</partNumber>
<partNumber>Volume: 21</partNumber>
<partNumber>Number: 7</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo><dateIssued encoding="w3cdtf">1994-07-01</dateIssued>
<copyrightDate encoding="w3cdtf">1994</copyrightDate>
</originInfo>
<subject usage="primary"><topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 27</identifier>
<recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF00285586</identifier>
<identifier type="matrixNumber">Art8</identifier>
<identifier type="local">BF00285586</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part><extent unit="pages"><start>640</start>
<end>646</end>
</extent>
</part>
<recordInfo><recordOrigin>Springer-Verlag, 1994</recordOrigin>
<recordIdentifier>259_1994_Article_BF00285586.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000207 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:259_1994_Article_BF00285586.pdf
   |texte=   Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)
}}

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024

	Serveur d'exploration sur l'Indium
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'Indium

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

Comparative biodistribution of indium- and yttrium-labeled B3 monoclonal antibody conjugated to either 2-(p-SCN-Bz)-6-methyl-DTPA (1 B4M-DTPA) or 2-(p-SCN-Bz)-1,4,7,10-tetraazacyclododecane tetraacetic acid (2B-DOTA)

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri